Bleomycin-induced pulmonary toxicity can have a significant impact on patient outcomes. However, no guidelines for ideal screening and monitoring are available. This paper reviews the literature to identify the best way to monitor and reduce patient risk for bleomycin pulmonary toxicity. We have created evidence-based guidelines to help healthcare professionals identify patient risk factors and provide appropriate assessment and monitoring for patients receiving bleomycin therapy.
Howlader N, Noone AM, Krapcho M, et al. (eds) SEER cancer statistics review, 1975–2011. Bethesda, MD: National Cancer Institute, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER website, April 2014.
HayJShahzeidiSLaurentG. Mechanisms of bleomycin-induced lung damage. Arch Toxicol1991; 65: 81–94.
4.
BöllBGörgenHFuchsM. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin study group HD10 and HD11 trials. J Clin Oncol2013; 31: 1522–1529.
5.
LazoJSBolandCJSchwartzPE. Bleomycin hydrolase activity and cytotoxicity in human tumors. Cancer Res1982; 42: 4026–4031.
6.
CarverJRShapiroCLNgA. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol2007; 25: 3991–4008.
ComisRLKuppingerMSGinsbergSJ. Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Res1979; 39: 5076–5080.
9.
MirLMTounektiOOrlowskiS. Bleomycin: revival of an old drug. Gen Pharmacol1996; 27: 745–748.
10.
O’SullivanJMHuddartRANormanAR. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol2003; 14: 91–96.
11.
LowerEEStrohoferSBaughmanRP. Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide. Am J Med Sci1988; 295: 193–197.
12.
GoldinerPLCarlonGCCvitkovicE. Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J1978; 1: 1664–1667.
van HulstRARietbroekRCGaastraMTW. To dive or not to dive with bleomycin: a practical algorithm. Aviat Space Environ Med2011; 82: 814–818.
15.
de WitRSleijferSKayeSB. Bleomycin and scuba diving: where is the harm. Lancet Oncol2007; 8: 954–955.
16.
CoudercLJStelianidesSFrachonI. Pulmonary toxicity of chemotherapy and G/G-MCSF: a report of five cases. Respir Med1999; 93: 65–68.
17.
MartinWGRistowKMHabermannTM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s Lymphoma. J Clin Oncol2005; 23: 7614–7620.
18.
SleijferSvan der MarkTWSchraffordt KoopsH. Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect. Br J Cancer1995; 71: 120–123.
19.
HoughtonBBGrimisonPSTonerGC. The effect of pulmonary function testing on bleomycin dosing in germ cell tumors. J Clin Oncol2011; 29 (suppl 7; abstr 227).
20.
GrimisonPSStocklerMRChatfieldM. Accelerated BEP for metastatic germ cell tumours: a multiceneter phase II trial by the Australian and New Zealand urogenital and prostate cancer trials group (ANZUP). Ann Oncol2014; 25: 143–148.
21.
MillerMRCrapoRHankinsonJ. General considerations for lung function testing. Eur Respir J2005; 26: 153–161.
22.
ComisRL. Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol1990; 8: 765–767.
